Elevated fasting plasma level of islet amyloid polypeptide (IAPP) in chronic alcoholic pancreatitis (CAP)

Hepato-Gastroenterology

Volumn 50, Issue 49, 2003, Pages 258-262

  Gasiorowska, Anita ^b   Orszulak Michalak, Daria ^b   Kozlowska, Alicja ^b   Malecka Panas, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NONE

Author keywords

Amylin; Chronic alcoholic pancreatitis; Pancreatic endocrine function

Indexed keywords

AMYLIN; C PEPTIDE; INSULIN;

ADULT; AGED; ALCOHOLIC PANCREATITIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GLUCOSE INTOLERANCE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

ADULT; AGED; AMYLOID; ANTI-ULCER AGENTS; C-PEPTIDE; ENDOCRINE SYSTEM DISEASES; FASTING; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; PANCREATITIS, ALCOHOLIC; SEVERITY OF ILLNESS INDEX;

EID: 12244256105     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Levitt N, Adams G, Salmon J, et al: The prevalence and severity of microvascular complications in pancreatic diabetes and IDDM. Diabetes Care; 1995; 18:971-974.
2. Domschke S, Bloom SR, Adrian TE: Chronic pancreatitis and diabetes mellitus plasma and gastroduodenal mucosal profiles of regulatory peptides (gastrin, motilin, secretin, cholecystokinin, gastrin inhibitory polypeptide, somatostatin, VIP, substance P, pancreatic polypeptide, glucagon, enteroglucagon, neurotensin. Hepatogastroenterology 1988; 35:229-237.
3. Mergener K, Baillie J: Chronic pancreatitis. Lancet 1997; 350:1379-1385.
4. Raue G, Keim V: Secondary diabetes in chronic pancreatitis. Z Gastroenterol 1999; Suppl 1:4-9.
5. Kalthoff BL, Layer P, Clain JE, et al: The course of alcoholic and non-alcoholic chronic pancreatitis. Dig Dis Sci 1984; 29:953.
6. Malecka-Panas E, Juszynski A, Wilamski E: Acute alcoholic pancreatitis does not lead to complete recovery. Mat Med Pol 1996; 28:64-68.
7. Malecka-Panas E, Juszynski A, Gasiorowska A, et al: Late outcome of pancreatic pseudocysts- a late complication of acute pancreatitis induced by alcohol. Med Sci Monit 1998; 4:465-472.
8. Cavalini G, Vaona B, Bovo P, et al: Diabetes in chronic alcoholic pancreatitis: role of residual beta-cell function and insulin resistance. Dig Dis Sci 1993; 38:497-501.
9. Westermark P, Wernstedt C, Wilander E, et al: Amyloid fibrils in human insulinoma and islets Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987; 84:3881-3885.
10. Cooper GJS, Willis AC, Clark A, et al: Purification and characterization of peptide from amyloid-rich pancreases of Type II diabetic patients. Proc Natl Acad Sci USA 1987; 84:8628-8632.
11. Young DA, Deems RO, Deacon RW, et al: Effects of amylin on glucose metabolism and glycolysis in vivo and in vitro. Am J Physiol 1990; 259:E457-E461.
12. Frontoni S, Choi SB, Banduch D, et al: In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991; 40:568-573.
13. Hoppener JWM, Oosterwijk C, Nieuwenhuis MG, et al: Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 1999; 42:427-434.
14. Furnsinn C, Leeuvenink H, Roden M, et al: Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am J Physiol 1994; 267:E300-E305.
15. Permert J, Ihse I, Jorfeldt L, et al: Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159:101-103.
16. Permert J, Ihse I, Jorfeldt L, et al: Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80:1047-1050.
17. Permert J, Larsson J, Gunilla T, et al: Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330:313-318.
18. Ding X, Flatt P, Permert J, et al: Pancreatic cancer cells selectively stimulate islet β cells to secrete amylin. Gastroenterology 1988; 114:130-138.
19. 2+] I and stimulates the release of pancreatic digestive enzymes from rat acinar AR42J cells: for an exclusive receptor system of amylin. Peptides 1996; 17:497-502.
20. Frey C: Classification of pancreatitis-state of the art. Pancreas 1986; 1:62-68.
21. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Organization, 1985 (Tech. Rep. Ser., no727).
22. Hartter E, Svoboda T, Ludvik B, et al: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34:52-54.
23. Van Jaarsveld BC, Hackeng WHL, Nieuwenhuis MG, et al: Islet amyloid polypeptide in human plasma. Lancet 1990; 335;69. (Letter)
24. Sanke T, Hanabusa T, Nakano Y, et al: Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34:129-132.
25. Philips A, Abu-Zidan F, Bonham M, et al: Amylin and severe acute pancreatitis. Pancreas 2000: 20:105-106.
26. Clodi M, Thomaseth K, Pacinio G, et al: Distribution and kinetics of amylin in humans. Am J Physiol (Endocrinol Metab 37) 1998; 274:E903-E908.
27. Sugawara K, Kobayashi T, Nakanishi K, et al: Marked islet amyloid polypeptide-positive amyloid deposition: a possible cause of severely insulin-deficient diabetes mellitus with atrophied exocrine pancreas. Pancreas 1993; 8:312-315.
28. Larsen S, Hilsted J, Tronier B, et al: Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis. Metabolism 1987; 36:964-967.
29. Enoki S, Mitsukawa T, Takemura J, et al: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin dependent diabetes mellitus. Diab Res Clin Pract 1992; 15:97-102.
30. Eriksson J, Nakazato M, Miyazato M, et al: Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing Type-2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35:291-293.
31. Olefsky M, Kolterman OG, Scarlet JA: Insulin action and resistance in obesity and non-insulin dependent Type II diabetes mellitus. Am J Physiol 1982; 243:E15-E30.
32. Mulder H, Ahren B, Stridsberg M, et al: Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 1995; 38:395-402.
33. Leckstrom A, Ostenson CG, Efendic S: Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas 1996; 13:259-267.
34. Warram JH, Martin BC, Krolewski AS, et al: Slow glucose removal rate of hyperinsulinemia precede the development of Type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113:909-915.
35. Tirpitz C, Glasbrenner B, Mayer D, et al: Comparison of different endocrine stimulation tests in nondiabetic patients with chronic pancreatitis. Hepatogastroenterology 1998; 45:1111-1116.
36. Kloppel G, Bommer G, Commandeur G, Heitz Ph: The endocrine pancreas in chronic pancreatitis:Immunocytochemical and ultrastructural studies. Virchows Arch [Pathol Anat] 1978; 377:154-174.
37. Cooper GJS: Amylin compared with calcitonin gene related peptide: structure, biology, and relevance to metabolic disease. Endocrinol Rev 1994; 15:163-201.
38. Drucker D: Perpectives in diabetes: glucagon-like peptides. Diabetes 1998; 47:159-169.